Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Blood Adv (2021) 5 (19): 3862–3872.

https://doi.org/10.1182/bloodadvances.2021004778

Published: 2021

Includes: Supplemental data

Journal Articles

Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma

Susanne Jung, Jochen Greiner, Stephanie von Harsdorf, Pavle Popovic, Roland Moll, Jens Schittenhelm, Kosmas Kandilaris, Volker Daniel, Alexander Kunz, Michael Schmitt, Peter Dreger

Blood Adv (2021) 5 (19): 3789–3793.

https://doi.org/10.1182/bloodadvances.2021004889

Published: 2021

Includes: Supplemental data

Journal Articles

The promise and perils of immunotherapy

Stefanie Lesch, Saar Gill

Blood Adv (2021) 5 (18): 3709–3725.

https://doi.org/10.1182/bloodadvances.2021004453

Published: 2021

Journal Articles

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Blood Adv (2021) 5 (18): 3623–3632.

https://doi.org/10.1182/bloodadvances.2021004645

Published: 2021

Includes: Supplemental data

Journal Articles

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Hasmukh Jain, Manju Sengar, Vasu Babu Goli, Jayashree Thorat, Prashant Tembhare, Dhanlaxmi Shetty, V. N. Avinash Bonda, Lingaraj Nayak, P. G. Subramanian, Bhausaheb Bagal, Nikhil Patkar, Neha Sharma, Himanshi Gupta, Sumeet Gujral

Blood Adv (2021) 5 (17): 3436–3444.

https://doi.org/10.1182/bloodadvances.2020003368

Published: 2021

Journal Articles

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Blood Adv (2021) 5 (17): 3397–3406.

https://doi.org/10.1182/bloodadvances.2020003885

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Blood Adv (2021) 5 (14): 2799–2806.

https://doi.org/10.1182/bloodadvances.2021004575

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Blood Adv (2021) 5 (13): 2775–2787.

https://doi.org/10.1182/bloodadvances.2021004233

Published: 2021

Includes: Supplemental data

Journal Articles

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Parastoo B. Dahi, Jasme Lee, Sean M. Devlin, Josel Ruiz, Molly Maloy, Carlos Rondon-Clavo, Erica Petrlik, Roni Tamari, Gunjan Shah, Michael Scordo, Matthew J. Matasar, Paul A. Hamlin, Esperanza Papadopoulos, Ann A. Jakubowski, Miguel-Angel Perales, Craig H. Moskowitz, Craig S. Sauter, Sergio A. Giralt

Blood Adv (2021) 5 (12): 2608–2618.

https://doi.org/10.1182/bloodadvances.2020004167

Published: 2021

Includes: Supplemental data

Journal Articles

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers

Sophie Paczesny, Marcelo C. Pasquini, Steven Z. Pavletic, Amit Agarwal, Stephen Spellman, Leslie Kean, Chantale Bernatchez, Juliane Gust, Verena Staedtke, Miguel-Angel Perales

Blood Adv (2021) 5 (11): 2519–2522.

https://doi.org/10.1182/bloodadvances.2021004604

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond

Blood Adv (2021) 5 (9): 2438–2446.

https://doi.org/10.1182/bloodadvances.2020003895

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Hyehyun Jeong, Hyungwoo Cho, Hyeyeong Kim, Heejung Chae, Jung-Bok Lee, Kyoungmin Lee, Shin Kim, Sang-wook Lee, Jin-Sook Ryu, Kyung Won Kim, Eun Jin Chae, Jooryung Huh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh

Blood Adv (2021) 5 (8): 2142–2152.

https://doi.org/10.1182/bloodadvances.2020003947

Published: 2021

Includes: Supplemental data

Journal Articles

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

Isabelle A. van Zeventer, Jonas B. Salzbrunn, Aniek O. de Graaf, Bert A. van der Reijden, H. Marike Boezen, Judith M. Vonk, Pim van der Harst, Jan Jacob Schuringa, Joop H. Jansen, Gerwin Huls

Blood Adv (2021) 5 (8): 2115–2122.

https://doi.org/10.1182/bloodadvances.2020004062

Published: 2021

Includes: Supplemental data

Journal Articles

Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study

Blood Adv (2021) 5 (7): 1837–1847.

https://doi.org/10.1182/bloodadvances.2020003453

Published: 2021

Includes: Supplemental data

Journal Articles

Involved-site radiotherapy for Helicobacter pylori –independent gastric MALT lymphoma: 26 years of experience with 178 patients

Joachim Yahalom, Amy J. Xu, Ariela Noy, Stephanie Lobaugh, Monica Chelius, Karen Chau, Carol Portlock, Carla Hajj, Brandon S. Imber, David J. Straus, Craig H. Moskowitz, Morton Coleman, Andrew D. Zelenetz, Zhigang Zhang, Ahmet Dogan

Blood Adv (2021) 5 (7): 1830–1836.

https://doi.org/10.1182/bloodadvances.2020003992

Published: 2021

Journal Articles

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Jeremy S. Abramson, Tanya Siddiqi, Jacob Garcia, Christine Dehner, Yeonhee Kim, Andy Nguyen, Sophie Snyder, November McGarvey, Matthew Gitlin, Corey Pelletier, Monika P. Jun

Blood Adv (2021) 5 (6): 1695–1705.

https://doi.org/10.1182/bloodadvances.2020003531

Published: 2021

Journal Articles

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Alden A. Moccia, Kimberly Schaff, Ciara Freeman, Paul J. Hoskins, Richard J. Klasa, Kerry J. Savage, Tamara N. Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn

Blood Adv (2021) 5 (5): 1483–1489.

https://doi.org/10.1182/bloodadvances.2020002982

Published: 2021

Includes: Supplemental data

Journal Articles

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings

Margaret L. MacMillan, Keli L. Hippen, David H. McKenna, Diane Kadidlo, Darin Sumstad, Todd E. DeFor, Claudio G. Brunstein, Shernan G. Holtan, Jeffrey S. Miller, Erica D. Warlick, Daniel J. Weisdorf, John E. Wagner, Bruce R. Blazar

Blood Adv (2021) 5 (5): 1425–1436.

https://doi.org/10.1182/bloodadvances.2020003219

Published: 2021

Includes: Supplemental data

Journal Articles

HLA-haploidentical TCRαβ + /CD19 + -depleted stem cell transplantation in children and young adults with Fanconi anemia

Luisa Strocchio, Daria Pagliara, Mattia Algeri, Giuseppina Li Pira, Francesca Rossi, Valentina Bertaina, Giovanna Leone, Rita Maria Pinto, Marco Andreani, Emanuele Agolini, Katia Girardi, Stefania Gaspari, Lavinia Grapulin, Francesca del Bufalo, Antonio Novelli, Pietro Merli, Franco Locatelli

Blood Adv (2021) 5 (5): 1333–1339.

https://doi.org/10.1182/bloodadvances.2020003707

Published: 2021

NARROW

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study

Fatal late-onset CAR T-cell–mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma

The promise and perils of immunotherapy

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma

Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma

Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Efficacy and safety of prophylactic high-dose MTX in high-risk DLBCL: a treatment intent–based analysis

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study

Involved-site radiotherapy for Helicobacter pylori –independent gastric MALT lymphoma: 26 years of experience with 178 patients

Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings

HLA-haploidentical TCRαβ + /CD19 + -depleted stem cell transplantation in children and young adults with Fanconi anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only